CO2022004513A2 - Compuestos inhibidores de prmt5 mta–cooperativos - Google Patents
Compuestos inhibidores de prmt5 mta–cooperativosInfo
- Publication number
- CO2022004513A2 CO2022004513A2 CONC2022/0004513A CO2022004513A CO2022004513A2 CO 2022004513 A2 CO2022004513 A2 CO 2022004513A2 CO 2022004513 A CO2022004513 A CO 2022004513A CO 2022004513 A2 CO2022004513 A2 CO 2022004513A2
- Authority
- CO
- Colombia
- Prior art keywords
- prmt5
- mta
- cooperatives
- inhibitory compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a compuestos que inhiben la actividad de la proteína arginina N–metil transferasa 5 (PRMT5). En particular, la presente invención se refiere a compuestos, composiciones farmacéuticas y métodos de uso, tales como métodos para tratar el cáncer, utilizando los compuestos y las composiciones farmacéuticas de la presente invención.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962899575P | 2019-09-12 | 2019-09-12 | |
US201962942833P | 2019-12-03 | 2019-12-03 | |
US202062961371P | 2020-01-15 | 2020-01-15 | |
US202062994927P | 2020-03-26 | 2020-03-26 | |
US202063060261P | 2020-08-03 | 2020-08-03 | |
PCT/US2020/050457 WO2021050915A1 (en) | 2019-09-12 | 2020-09-11 | Mta-cooperative prmt5 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022004513A2 true CO2022004513A2 (es) | 2022-06-21 |
Family
ID=72659905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0004513A CO2022004513A2 (es) | 2019-09-12 | 2022-04-08 | Compuestos inhibidores de prmt5 mta–cooperativos |
Country Status (15)
Country | Link |
---|---|
US (3) | US11479551B2 (es) |
EP (1) | EP4028388A1 (es) |
JP (1) | JP2022548255A (es) |
KR (1) | KR20220083691A (es) |
CN (1) | CN114728912A (es) |
AU (1) | AU2020345899A1 (es) |
BR (1) | BR112022004248A2 (es) |
CA (1) | CA3150515A1 (es) |
CL (1) | CL2022000603A1 (es) |
CO (1) | CO2022004513A2 (es) |
IL (1) | IL290341A (es) |
MX (1) | MX2022002938A (es) |
NO (1) | NO20220309A1 (es) |
TW (1) | TW202122387A (es) |
WO (1) | WO2021050915A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022192745A1 (en) * | 2021-03-11 | 2022-09-15 | Mirati Therapeutics, Inc. | Mta-cooperative prmt5 inhibitors |
KR20230167053A (ko) | 2021-04-08 | 2023-12-07 | 미라티 테라퓨틱스, 인크. | 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법 |
KR20230167050A (ko) | 2021-04-08 | 2023-12-07 | 미라티 테라퓨틱스, 인크. | 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법 |
KR20240019172A (ko) * | 2021-06-02 | 2024-02-14 | 아이디어야 바이오사이언시스 인코포레이티드 | Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법 |
WO2023059798A1 (en) | 2021-10-06 | 2023-04-13 | Mirati Therapeutics, Inc. | Methods for separation of enantiomers |
CA3233157A1 (en) | 2021-10-06 | 2023-04-13 | Peter Olson | Combination therapies using prmt5 inhibitors for the treatment of cancer |
WO2023081367A2 (en) | 2021-11-05 | 2023-05-11 | Mirati Therapeutics, Inc. | 2-amino imidazole derivatives |
AU2022401750A1 (en) * | 2021-11-30 | 2024-02-15 | Abbisko Therapeutics Co., Ltd. | Pyrazole derivative, and preparation method therefor and use thereof in medicine |
WO2023125540A1 (zh) * | 2021-12-27 | 2023-07-06 | 南京明德新药研发有限公司 | 吡唑-1(2h)-酞嗪酮类化合物及其应用 |
CN114315735B (zh) * | 2021-12-29 | 2023-08-01 | 广州中医药大学(广州中医药研究院) | 一种鲁米诺酯化衍生物及其制备方法与应用 |
CN116903611A (zh) * | 2022-01-26 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用 |
WO2023174250A1 (en) * | 2022-03-15 | 2023-09-21 | Beigene , Ltd. | 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5 |
WO2023202626A1 (zh) * | 2022-04-22 | 2023-10-26 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
CN117843634A (zh) * | 2022-05-24 | 2024-04-09 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
WO2024008176A1 (zh) * | 2022-07-07 | 2024-01-11 | 西藏海思科制药有限公司 | 一种可抑制prmt5·mta的杂环化合物及其用途 |
CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
WO2024022186A1 (zh) * | 2022-07-29 | 2024-02-01 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
WO2024038004A1 (en) | 2022-08-15 | 2024-02-22 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
WO2024049948A1 (en) | 2022-09-01 | 2024-03-07 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0017518D0 (en) * | 2000-07-17 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
ES2287170T3 (es) * | 2000-10-12 | 2007-12-16 | MERCK & CO., INC. | Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa. |
US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
-
2020
- 2020-09-11 US US16/948,312 patent/US11479551B2/en active Active
- 2020-09-11 KR KR1020227011812A patent/KR20220083691A/ko unknown
- 2020-09-11 CN CN202080073827.9A patent/CN114728912A/zh active Pending
- 2020-09-11 EP EP20781175.3A patent/EP4028388A1/en active Pending
- 2020-09-11 MX MX2022002938A patent/MX2022002938A/es unknown
- 2020-09-11 TW TW109131387A patent/TW202122387A/zh unknown
- 2020-09-11 WO PCT/US2020/050457 patent/WO2021050915A1/en active Application Filing
- 2020-09-11 BR BR112022004248A patent/BR112022004248A2/pt unknown
- 2020-09-11 US US17/018,738 patent/US11492351B2/en active Active
- 2020-09-11 AU AU2020345899A patent/AU2020345899A1/en active Pending
- 2020-09-11 JP JP2022516295A patent/JP2022548255A/ja active Pending
- 2020-09-11 CA CA3150515A patent/CA3150515A1/en active Pending
-
2022
- 2022-02-03 IL IL290341A patent/IL290341A/en unknown
- 2022-03-11 CL CL2022000603A patent/CL2022000603A1/es unknown
- 2022-03-11 NO NO20220309A patent/NO20220309A1/en unknown
- 2022-04-08 CO CONC2022/0004513A patent/CO2022004513A2/es unknown
- 2022-09-12 US US17/942,367 patent/US20230054883A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020345899A1 (en) | 2022-03-03 |
MX2022002938A (es) | 2022-05-26 |
TW202122387A (zh) | 2021-06-16 |
US11492351B2 (en) | 2022-11-08 |
NO20220309A1 (en) | 2022-03-11 |
CL2022000603A1 (es) | 2023-01-27 |
US11479551B2 (en) | 2022-10-25 |
EP4028388A1 (en) | 2022-07-20 |
KR20220083691A (ko) | 2022-06-20 |
WO2021050915A1 (en) | 2021-03-18 |
JP2022548255A (ja) | 2022-11-17 |
US20230054883A1 (en) | 2023-02-23 |
US20210078994A1 (en) | 2021-03-18 |
BR112022004248A2 (pt) | 2022-05-31 |
CA3150515A1 (en) | 2021-03-18 |
CN114728912A (zh) | 2022-07-08 |
IL290341A (en) | 2022-04-01 |
US20210079003A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022004513A2 (es) | Compuestos inhibidores de prmt5 mta–cooperativos | |
CO2022010241A2 (es) | Inhibidores de sos1 | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
ECSP20079887A (es) | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1 | |
CO2018002063A2 (es) | Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
ECSP22016571A (es) | Compuestos inhibidores de rip1 y m?todos para hacer y utilizar los mismos | |
CO2019011543A2 (es) | Inhibidores de pd-1/pd-l1 | |
CL2019001709A1 (es) | Derivados pirazol como inhibidores de malt1. | |
BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
BR112019004100A2 (pt) | compostos de biarila úteis como imunomoduladores | |
CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2017011183A2 (es) | Inhibidores de indolamina-2,3-dioxigenasa composiciones que los contienen y métodos de preparación | |
BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
ECSP22016567A (es) | Compuestos inhibidores de rip1 y m?todos para prepararlos y usarlos | |
BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio |